VÊPRES carried out for ADRAGOS PHARMA the expansion of their drug substance production site in France. A large-scale project carried out under demanding conditions.
Creation of a new production line
The French site of the German Adragos Pharma group in Livron (Drôme) houses a production unit for injectable medicinal substances and suppositories.
The project involved expanding the site. Vêpres built a new line to increase production capacity. The major works were carried out between February 2023 and February 2024. The program was part of the Plan France Relance launched by the government in 2020 to revive economic activity, hit by the health crisis, and build the France of 2030.
" VÊPRES managed the complexity of the project perfectly."
Gaël LE SAUX, Director of ADRAGOS PHARMA's French site
A new production line built on a site with many constraints. (...)
The creation of this new production line required all the expertise and rigor of the VÊPRES teams. As this was an extension to a very old building with an arched vault structure, we necessarily had to adapt to the existing structure. The aeraulic network was therefore distributed from the outside, from the first floor to the upper storey (R+2). The project required a complete overhaul of the shell and slab, as well as raising the roof on the first floor.
The work was carried out in parallel with our customer's operations, with no interruption to production, requiring meticulous organization and discretion. Demanding conditions that our teams are used to managing.
In a restricted working and storage environment, and faced with asbestos removal constraints, VÊPRES successfully completed an ambitious project in the delicate context of working in an old building.
Services provided
- Production site expansion
- Work from February 2023 to February 2024
- Air network distribution
- Complete refurbishment of shell and slab
- Raising the roof on the first floor
- Work carried out without interrupting production
A new production line
VÊPRES designed a new production line for ADRAGOS PHARMA's Livron site in France. This large-scale program lasted a year, and involved adapting to numerous constraints due to the age of the site and the need to keep production running.